ArticleBMC cancer2026
Proteome profiling reveals early diagnostic biomarker candidates for colorectal cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LC-MS/MS Profiling of Blood Serum Reveals Disease-Enriched Peptides in Metabolic Syndrome.Journal of personalized medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is the third most common cancer worldwide. Advanced CRC has a grim prognosis, so there is a high demand for an early non-invasive diagnostic biomarker.
methodsWe present a colorectal tissue-serum proteomics approach combined with external database analysis to identify early diagnostic biomarkers specific to CRC. Subsequently, RT-qPCR, PRM, and ELISA experiments were employed to validate the biomarkers in an independent CRC case-control group. Furthermore, in vitro experiments were conducted to investigate the implications of a biomarker on CRC cell phenotyping.
resultsNine proteins (CA1, HBD, SMPDL3A, HBB, ALAD, S100A4, RAB27B, HBA2, CAT) were identified as potential diagnostic biomarkers. Among them, CA1 and SMPDL3A exhibited CRC specificity. The combination of CA1 and SMPDL3A demonstrated superior diagnostic efficacy in CRC (AUC = 0.917; 95% CI = 0.877-0.957). The overexpression of SMPDL3A inhibits the migration and invasion of CRC cells.
conclusionsCA1 and SMPDL3A proteins are promising novel specific biomarkers for the early diagnosis of CRC. However, larger prospective trials are necessary to validate their clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.